A Phase 1/2 study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of FT-2102 with or without azacitidine or cytarabine in patients with AML or MDS with an IDH-1 mutation.


Acute Myeloid Leukaemia (AML) and high risk Myelodysplasia (MDS).


The bone marrow is like a factory, producing all types of blood cells. This process begins with immature stem cells in the bone marrow, and results in production of mature red cells, platelets and different types of white cells.

Myelodysplasia (MDS) is a type of cancer of bone marrow cells. In MDS, the stem cells are damaged, which results in the production of abnormal, clonal blood cells. This may lead to inadequate production of any blood cell type, and may result in anaemia, bleeding, bruising or increased infections.

Acute myeloid leukaemia (AML) is an aggressive cancer of the bone marrow. In AML, there is an overproduction of immature white cells, known as blasts. These immature cells do not function properly to prevent and fight infection, and can result in production of inadequate numbers of red cells and platelets, which in turn may lead to anaemia, bleeding and bruising.

MDS can evolve into AML. The prognosis of MDS, including the risk of progression to AML, is calculated using a risk score which takes into account blood counts, number of blast cells seen on bone marrow testing, and genetic changes within the abnormal bone marrow cells. There are also a range of molecular markers that may be mutated in abnormal cells in MDS or AML and may affect prognosis. One such marker is IDH-1. This is expressed in around 10% of AML and 3% of MDS.

New drugs that target a range of molecular mutations are being developed for use in MDS and AML – including drugs that target mutated IDH-1 (IDH-1 inhibitors).

The aim of this study is to understand the safety and activity of FT2102 (an IDH-1 inhibitor) as a single agent, and in combination with accepted standard treatments for AML and MDS – Azacytadine or Cytarabine, in people with MDS or AML and who have been show to have the IDH-1 mutation.


Include, but not limited to, the following:

Included, but not limited to, the following:
- A confirmed diagnosis of AML or intermediate, high risk or very high risk MDS, excluding a subtype of AML called APML.
- Evidence of IDH1-R132 mutation.
- MDS or AML in the following settings:
1) Patients with a relapse of AML/MDS having been previously successfully treated, OR
2) Patients with AML/MDS that has not responded to previous treatment, OR
3) Patients who have never received treatment for AML/MDS, but in whom standard treatments would be contraindicated, OR
4) People who have responded well to initial treatment for MDS/AML but in whom the IDH-1 mutation is still detectable at a low level
- No other active cancers in the last twelve months (except for some cancers cured with minor operations such as early skin cancer).
- No symptoms of advanced heart failure

Contact person:

Louise Hay
Phone 6457 7600


Principal Investigator:

Dr Carolyn Grove

6457 7600


Forma Therapeutics Inc.



Protocol Number:


Trial Registration Number:



ANZ Clinical Trial Registry